Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | RXRB | P28702 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | XBP1 | P17861 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8768764 | 0.87 | MRGPRX4 (0.58) | MRGPRX4HPGDRXRARXRBNPC1 | |
| SCHEMBL8356708 | 0.87 | NPC1 (0.64) | HPGDRXRANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL243754 | 0.85 | MRGPRX4 (0.73) | MRGPRX4HPGDRXRARXRBNPC1 | |
| SCHEMBL3161913 | 0.85 | MRGPRX4 (0.56) | MRGPRX4HPGDRXRARXRBNPC1 | |
| SCHEMBL4295650 | 0.84 | FOLH1 (0.62) | HPGDRXRARXRBNPC1RAB9A | |
| SCHEMBL10604837 | 0.84 | EGFR (0.65) | HPGDNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL8756076 | 0.84 | MRGPRX4 (0.61) | MRGPRX4HPGDRXRARXRBNPC1 | |
| Hydrochloric Acid SCHEMBL9647665 | 0.84 | MRGPRX4 (0.71) | MRGPRX4HPGDRXRARXRBNPC1 | |
| SCHEMBL4161097 | 0.83 | NPC1 (0.53) | MRGPRX4HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28979208 | 0.83 | NPC1 (0.53) | HPGDNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1673366-A1 | 1-\"2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL]-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035522-A1 | 1-‘2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL!-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2005-04-21 | — | — | WO | disclosed |
| EP-0579833-B1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0579833-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992018461-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | MRGPRX4 441/4885HPGD 1162/4885RXRA 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.